Knockout to human MAb

4-Antibody AG says its technology for generating monoclonal antibodies combines the strengths of using mice to generate human antibodies with the ability to select for high affinity antibodies, even as it skirts IP claimed by other techniques that do the same things.

Investors recently provided the company with CHF17 million

Read the full 503 word article

How to gain access

Continue reading with a
two-week free trial.